Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal

Rhea-AI Summary

Microbot Medical (NASDAQ: MBOT) announced publication of the ACCESS-PVI pivotal study in the Journal of Vascular and Interventional Radiology on March 24, 2026. The multicenter feasibility study completed in 2025 and underwent independent peer review. The LIBERTY system received FDA clearance in September 2025 and had a limited market release in late 2025, with a planned full market release at the SIR conference in April 2026.

The publication strengthens the clinical evidence base supporting broader commercial adoption of the single-use LIBERTY endovascular robotic system.

Positive

• Peer-reviewed publication in JVIR on March 24, 2026
• ACCESS-PVI multicenter feasibility study completed in 2025
• U.S. FDA clearance received in September 2025
• Limited market release in late 2025; full release planned April 2026

Negative

• Broader commercial adoption not yet achieved; evidence expansion ongoing
• Full market rollout remains pending until the SIR conference in April 2026

Key Figures

ACCESS-PVI completion: 2025 FDA clearance date: September 2025 Limited market release start: Late 2025 +5 more

8 metrics

ACCESS-PVI completion 2025 ACCESS-PVI pivotal study completion year

FDA clearance date September 2025 LIBERTY system FDA clearance for peripheral endovascular procedures

Limited market release start Late 2025 Commencement of LIBERTY limited market release

Planned full market release April 2026 Targeted full market release at SIR conference

Journal inception 1990 JVIR publication history since 1990

Current share price $2.52 Pre-news price vs 52-week range of $1.35–$4.67

52-week change vs high -46.04% Distance from 52-week high of $4.67

52-week change vs low 86.67% Distance above 52-week low of $1.35

Market Reality Check

Price: $2.52 Vol: Volume 1,214,077 is at 0....

low vol

$2.52 Last Close

Volume Volume 1,214,077 is at 0.55x the 20-day average of 2,218,230 shares. low

Technical Price $2.52 is trading slightly below the 200-day MA at $2.58.

Peers on Argus

MBOT was down 0.79% while key peers were mixed: AVR -4.7%, but KRMD, INFU, STXS,...

2 Up

MBOT was down 0.79% while key peers were mixed: AVR -4.7%, but KRMD, INFU, STXS, and NYXH were up between roughly 1–4%, pointing to stock-specific rather than sector-wide pressure.

Historical Context

5 past events · Latest: Mar 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 17	Conference participation	Positive	+1.1%	Roth conference appearance to discuss LIBERTY commercial progress and market release plans.
Mar 10	Conference participation	Positive	+2.9%	Oppenheimer MedTech conference debut highlighting LIBERTY limited release and growth drivers.
Mar 04	Policy alignment news	Positive	+2.5%	AMA radiation policy alignment positioning LIBERTY as a safety-focused robotic solution.
Mar 03	Operations update	Neutral	-3.6%	Statement of operational and commercial stability amid geopolitical events in the Middle East.
Feb 24	Hospital adoption	Positive	+23.9%	Tampa General Hospital becoming first Florida adopter of the LIBERTY robotic system.

Pattern Detected

Recent LIBERTY-focused news has generally seen positive price alignment, especially on commercialization and adoption updates.

Recent Company History

Over the last month, MBOT has repeatedly highlighted commercialization of its LIBERTY system, with conference participation on Mar 19 and Mar 23, 2026, AMA-aligned radiation safety messaging on Mar 4, 2026, operational stability amid geopolitical events on Mar 3, 2026, and the Tampa General Hospital adoption on Feb 24, 2026. Those events often coincided with positive moves, especially the 23.9% gain after the Tampa General announcement, framing today’s peer‑reviewed publication as another step in the same commercialization narrative.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-28

The company has an active Form S-3/A shelf amendment dated Oct 28, 2025. The amendment primarily updates procedural language for effectiveness under Section 8(a) of the Securities Act and does not modify the prospectus terms. The shelf is not yet effective, and there have been 2 related 424B3 usage filings recorded in Nov 2025.

Market Pulse Summary

This announcement underscores a key clinical milestone: JVIR’s peer‑reviewed publication of the ACCE...

Analysis

This announcement underscores a key clinical milestone: JVIR’s peer‑reviewed publication of the ACCESS‑PVI study, adding validation to LIBERTY’s September 2025 FDA clearance and limited market release that began in late 2025. It fits a pattern of building evidence and visibility ahead of the planned full release at SIR in April 2026. Investors may focus on additional clinical data, adoption by new centers, regulatory updates, and any capital-raising steps under the current shelf as they assess execution risk.

Key Terms

endovascular, interventional radiology, peripheral vascular interventions, peer-reviewed, +3 more

7 terms

endovascular medical

"developer and distributor of the innovative LIBERTY® Endovascular Robotic System"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

interventional radiology medical

"Journal of Vascular and Interventional Radiology (JVIR), titled “In Vivo Evaluation..."

Interventional radiology is a medical specialty that uses imaging tools (like X-rays, CT scans or ultrasound) as a live map to guide tiny instruments through small skin openings to diagnose or treat problems inside the body, replacing larger surgeries. For investors, it matters because these image-guided procedures often cut recovery time, reduce hospital stays and create steady demand for specialized devices, imaging equipment and related services, affecting healthcare costs and industry revenues.

peripheral vascular interventions medical

"Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions"

Procedures that open, clear or repair blood vessels outside the heart and brain — usually in the legs, arms or kidneys — to restore blood flow, often using catheters, balloons, stents or clot-removal devices. Investors care because demand for these treatments drives sales for medical device makers, hospitals and service providers; winning regulatory approval or gaining preference in clinical guidelines can be like securing a larger share of a recurring market, similar to a company landing a long-term supplier contract.

peer-reviewed technical

"a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study"

Peer-reviewed means a study, report or paper has been examined and approved by independent experts in the same field before publication, like having multiple qualified inspectors check a building plan. For investors, peer review signals that methods and conclusions have passed scrutiny beyond the author’s claims, making scientific, clinical or technical findings more reliable and reducing the chance that decisions or valuation are based on unchecked or flawed evidence.

fda clearance regulatory

"The LIBERTY system received U.S. Food and Drug Administration (FDA) clearance in September 2025"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

peripheral endovascular procedures medical

"single-use, remotely operated robotic system for peripheral endovascular procedures"

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

robotic system technical

"Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions"

A robotic system is a combination of machines, sensors and software that carries out physical tasks with various levels of independence — from guided arms on factory floors to medical robots that assist surgeons. For investors, robotic systems matter because they can lower labor costs, boost speed and precision, or enable new products and services; like a smart, tireless worker, they can change a company’s productivity, margins and growth potential.

AI-generated analysis. Not financial advice.

Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study

Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System

HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, which is already garnering medical and industry attention, today announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR), titled “In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study.” The article’s first author, Dr. Francois Cornelis, is a leading interventional radiologist specializing in neurointerventions and image-guided, minimally invasive therapies. He has a keen interest in robotics, AI, and advanced imaging, and served as the Lead Principal Investigator for the LIBERTY ACCESS PVI Pivotal Study.

The Journal of Vascular and Interventional Radiology, published continuously since 1990, is the premier peer-reviewed journal serving the global interventional radiologist community. Publication in a peer-reviewed journal is a significant milestone, signifying that the study’s methodology and data have been rigorously vetted by independent experts, ensuring a fair and balanced evaluation of the results.

This article provides a comprehensive, evidence-based analysis of the Company’s ACCESS-PVI study, which was completed in 2025 and presented at the Society of Interventional Radiology (SIR) annual meeting in April 2025. The study has now undergone rigorous independent peer review, which is considered the gold standard for clinical validation. The LIBERTY system received U.S. Food and Drug Administration (FDA) clearance in September 2025 for peripheral endovascular procedures.

“We are very pleased by the publication of the ACCESS-PVI results in JVIR, a leading voice in the field. This is a recognition that speaks to the quality and impact of the study,” commented Juan Diaz-Cartelle, Chief Medical Officer. “We would like to thank all the co-authors and we are looking forward to generating more clinical evidence that would foster appreciation for the benefits of the LIBERTY system.”

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

What did Microbot Medical (MBOT) announce on March 24, 2026 regarding the ACCESS-PVI study?

Microbot Medical announced publication of the ACCESS-PVI pivotal study in JVIR on March 24, 2026. According to Microbot Medical, the multicenter feasibility study was completed in 2025, underwent independent peer review, and complements FDA clearance for the LIBERTY system in September 2025.

How does the JVIR publication affect LIBERTY clinical validation for MBOT?

The JVIR publication provides independent peer-reviewed validation of ACCESS-PVI study methods and findings. According to Microbot Medical, this peer review is the gold standard and strengthens the clinical evidence supporting LIBERTY ahead of broader commercial rollout.

When did the LIBERTY system receive FDA clearance and what does that mean for MBOT?

LIBERTY received U.S. FDA clearance in September 2025 for peripheral endovascular procedures. According to Microbot Medical, this clearance enables limited market release and paves the way for a planned full market release at SIR in April 2026.

What is the timeline for LIBERTY commercial availability from Microbot Medical (MBOT)?

Microbot Medical began a limited market release of LIBERTY in late 2025 and plans a full market release at SIR in April 2026. According to Microbot Medical, the April 2026 showcase aims to deepen market adoption using published clinical evidence.

What evidence from the ACCESS-PVI study supports investor confidence in MBOT's LIBERTY system?

The ACCESS-PVI study is a multicenter feasibility trial completed in 2025 and now peer-reviewed in JVIR. According to Microbot Medical, publication signals rigorous independent review and contributes to the evidence base for LIBERTY's clinical utility.